Rifampicin News and Research

RSS

Certain HIV treatment less effective when used with rifampicin-based anti-tuberculosis therapy

Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

3 Aug 2008

New test quickly detects multi drug-resistant tuberculosis

Researchers have developed a new test which can quickly detect multi drug-resistant tuberculosis (MDR-TB).

1 Jul 2008

New rapid tests for drug-resistant TB for developing countries

People in low-resource countries who are ill with multidrug-resistant TB (MDR-TB) will get a faster diagnosis -- in two days, not the standard two to three months -- and appropriate treatment thanks to two new initiatives unveiled today by WHO, the Stop TB Partnership, UNITAID and the Foundation for Innovative New Diagnostics (FIND).

30 Jun 2008

Increasing transmission of drug resistant tuberculosis in the UK

A changing population structure and ongoing migration have increased cases of drug resistant tuberculosis, according to a study published on bmj.com today.

1 May 2008

Hard to treat TB case diagnosed in Britain

Health officials in Britain say they are dealing with the country's first case of a rare strain of tuberculosis (TB) which is almost untreatable.

24 Mar 2008

WHO ready to tackle drug resistant TB

According to the World Health Organization (WHO) some forms of tuberculosis (TB) are a threat to the security and stability of global health.

25 Jun 2007

New plan to contain extensively drug-resistant TB (XDR-TB)

Hundreds of thousands of cases of drug-resistant tuberculosis (TB) can be prevented and as many as 134 000 lives saved through the implementation of a two-year response plan, published/launched today by the World Health Organization (WHO) and the Stop TB Partnership.

22 Jun 2007

Extremely drug resistant TB a serious problem in India

Extremely drug resistant TB, or XDR-TB, is a serious problem in India, according to a study presented at the American Thoracic Society 2007 International Conference, on Monday, May 21.

22 May 2007

Patient adherence an essential factor for successful tuberculosis treatment

Nearly 2 million people die from tuberculosis each year, mainly in the poorest countries. The pathogen, Koch's bacillus, can pass easily by aerial infection from one individual to another. The spread of the disease, favoured by the Aids epidemic and the appearance of multi-resistant strains, has led WHO to make tuberculosis control one of the world's main health priorities.

27 Mar 2007

XDR-TB in South Africa

A team of medical ethics and public health experts say tough isolation measures, involuntary if need be, are justified to contain a deadly, contagious, drug-resistant strain of TB in South Africa and to prevent "a potentially explosive international health crisis."

23 Jan 2007

Measures to combat XDR-TB worldwide

Health experts have confirmed that the emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious threat to public health, particularly when associated with HIV.

17 Oct 2006

Extensive Drug Resistant TB now a major threat

The World Health Organization (WHO) has expressed concern over the emergence of virulent drug-resistant strains of tuberculosis (TB) and is calling for measures to be strengthened and implemented to prevent the global spread of the deadly TB strains.

5 Sep 2006

Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia

Long-term therapy with some antiepileptic drugs and antibiotics can cause osteomalacia, a condition marked by softening of the bones that is usually the result of vitamin D and calcium deficiency.

16 May 2006

New combination treatment that could dramatically shorten the length of tuberculosis treatment

The clinical results of a new combination treatment that could dramatically shorten the length of tuberculosis treatment were presented at a recent scientific conference in the USA. This virulent disease of the lungs still infects millions every year, with a notable resurgence in Europe, especially in the East.

10 Jan 2006

Hospital "super super bug" stronger than MRSA

According to reports eleven patients at a British hospital have acquired a superbug said to be stronger than MRSA.

11 Dec 2005

Inexpensive treatment stops multi-drug resistant TB in its tracks

A standard and inexpensive tuberculosis treatment regimen cut the overall TB rate in half and lowered the rate of drug-resistant cases even more dramatically in a remote Mexican health district with a high prevalence of the disease.

3 Apr 2005

Rifampicin can prevent the formation of protein fibrils associated with Parkinson's disease

Researchers at the University of California, Santa Cruz, have shown that rifampicin, an antibiotic used to treat leprosy and tuberculosis, can prevent the formation of protein fibrils associated with the death of brain cells in people with Parkinson's disease. The drug also dissolved existing fibrils in laboratory tests.

29 Nov 2004

WHO reports on treating tuberculosis in Ukraine

Multidrug-resistant TB (MDR-TB) is the disease caused by TB bacilli that are resistant to at least isoniazid and rifampicin – the two most powerful anti-TB drugs. It results from inconsistent or partial treatment of TB, and develops when public health programmes fail to deliver regular and reliable treatment to TB patients.

12 May 2004